The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. A randomized, placebo-controlled, double-blind crossover trial

L Taranto-Montemurro, L Messineo… - American journal of …, 2019 - atsjournals.org
Rationale: There is currently no effective pharmacological treatment for obstructive sleep
apnea (OSA). Recent investigations indicate that drugs with noradrenergic and …

The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity A Randomized, Placebo-controlled, Double-Blind Crossover …

L Taranto-Montemurro, L Messineo… - American Journal of …, 2019 - bv.fapesp.br
Rationale: There is currently no effective pharmacological treatment for obstructive sleep
apnea (OSA). Recent investigations indicate that drugs with noradrenergic and …

The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover …

L Taranto-Montemurro, L Messineo… - American Journal of …, 2019 - europepmc.org
Rationale: There is currently no effective pharmacological treatment for obstructive sleep
apnea (OSA). Recent investigations indicate that drugs with noradrenergic and …

The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover …

L Taranto-Montemurro, L Messineo… - … of respiratory and …, 2019 - pubmed.ncbi.nlm.nih.gov
Rationale: There is currently no effective pharmacological treatment for obstructive sleep
apnea (OSA). Recent investigations indicate that drugs with noradrenergic and …

[HTML][HTML] The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind …

L Taranto-Montemurro, L Messineo… - American Journal of …, 2019 - ncbi.nlm.nih.gov
Rationale: There is currently no effective pharmacological treatment for obstructive sleep
apnea (OSA). Recent investigations indicate that drugs with noradrenergic and …

The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity a randomized, placebo-controlled, double-blind crossover trial

L Taranto-Montemurro, L Messineo… - … of respiratory and …, 2019 - researchnow.flinders.edu.au
Rationale: There is currently no effective pharmacological treatment for obstructive sleep
apnea (OSA). Recent investigations indicate that drugs with noradrenergic and …

The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity A Randomized, Placebo-controlled, Double-Blind Crossover …

L TARANTO-MONTEMURRO… - American Journal of …, 2019 - observatorio.fm.usp.br
Rationale: There is currently no effective pharmacological treatment for obstructive sleep
apnea (OSA). Recent investigations indicate that drugs with noradrenergic and …

The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity: A Randomized, Placebo-controlled, Double-Blind Crossover …

L Taranto-Montemurro, L Messineo… - American Journal of …, 2019 - search.proquest.com
Rationale: There is currently no effective pharmacological treatment for obstructive sleep
apnea (OSA). Recent investigations indicate that drugs with noradrenergic and …

The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity a randomized, placebo-controlled, double-blind crossover trial

L Taranto-Montemurro, L Messineo… - American Journal of …, 2019 - research.monash.edu
Rationale: There is currently no effective pharmacological treatment for obstructive sleep
apnea (OSA). Recent investigations indicate that drugs with noradrenergic and …

[引用][C] The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind …

L Taranto-Montemurro, L Messineo, SA Sands… - American Journal of …, 2019 - cir.nii.ac.jp
The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea
Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial | CiNii Research …